Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2017-04-30 Declaration of Voting R…
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'Total Voting Rights Announcement' released on 30.04.2017, specifically referencing Article 26a of the WpHG (German Securities Trading Act). It details a capital measure ('Conditional capital increase') and reports the new total number of voting rights (553,654,349). This type of announcement, which reports on changes related to capital structure or voting rights, fits best under the 'Capital/Financing Update' category (CAP) or potentially a general 'Regulatory Filing' (RNS). Since it explicitly details a capital measure ('Conditional capital increase') and reports the resulting share count, CAP is the most specific fit, although it is also a regulatory disclosure. Given the options, 'CAP' covers the substance of the change reported (capital structure/voting rights), while 'RNS' is a fallback. I will classify it as CAP due to the specific content regarding capital measures.
2017-04-30 English
Telefonkonferenz zur Übernahme von Akorn und des Biosimilars-Geschäfts der Merck KGaA
Capital/Financing Update Classification · 95% confidence The document is dated April 25, 2017, and details two major corporate actions: the acquisition of Akorn and the acquisition of Merck KGaA's Biosimilars Business. It includes transaction highlights, financial outlooks, synergy estimates, and due diligence processes. This content is characteristic of a major corporate announcement intended for investors and the market, often released prior to or alongside a formal regulatory filing. Since it is a detailed announcement of significant corporate activity (M&A and financing implications), it fits best under Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were a general announcement. However, the focus on acquisition terms, synergies, and financial outlook strongly points towards a Capital/Financing Update (CAP) as it details fundraising/financing aspects (fully debt-financed) and major structural changes. It is not a 10-K (Annual Report), IR (Interim Report), or ER (Earnings Release). It is too detailed for a simple RPA or RNS fallback, and directly concerns capital structure changes and financing activities related to acquisitions.
2017-04-25 English
Fresenius SE & Co. KGaA: Fresenius Kabi to strengthen and diversify product portfolio by acquiring Akorn and Merck KGaA's biosimilars business
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated April 24, 2017, disclosing inside information according to Article 17 MAR. The core content details two significant corporate actions: the acquisition of Akorn, Inc. and the acquisition of Merck KGaA’s biosimilars business. These actions involve major financing, potential changes in capital structure, and strategic business shifts. This type of announcement, detailing significant corporate transactions like mergers and acquisitions, fits best under the 'Capital/Financing Update' category (CAP) or potentially 'Regulatory Filings' (RNS) if it were a general disclosure. However, since the primary focus is on the financing and structure changes resulting from the acquisitions, 'CAP' is a strong candidate. Given the nature of the announcement—a major transaction involving purchase prices, debt financing, and expected accretion/dilution—it is fundamentally a capital/financing event. It is not an Earnings Release (ER), Interim Report (IR), or a standard M&A announcement (TAR) which usually relates to a bid/takeover, but rather a definitive agreement announcement heavily focused on the financial implications and funding.
2017-04-24 English
Konzernabschluss zum Geschäftsjahr vom 01.01.2016 bis zum 31.12.2016
Annual Report Classification · 100% confidence The document is titled 'Fresenius SE & Co. KGaA IFRS Konzernabschluss 2016' and explicitly identifies itself as the 'Konzernabschluss und Konzern-Lagebericht' (Consolidated Financial Statements and Management Report) for the fiscal year 2016. It contains detailed financial performance data, business model descriptions, and management analysis. As it covers the full fiscal year and provides comprehensive financial statements and management commentary, it is classified as an Annual Report (10-K equivalent in the context of international reporting). FY 2016
2017-04-11 German
Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms discussions with Akorn, Inc.
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated April 7, 2017, explicitly stating that Fresenius SE & Co. KGaA confirms discussions regarding a 'potential acquisition of Akorn, Inc.' The key word identified in the metadata is 'Mergers & Acquisitions'. This content directly relates to a proposal or bid concerning a merger or takeover. Therefore, the appropriate classification is M&A Activity (TAR). The document is short and is an announcement, not the final agreement or detailed report.
2017-04-07 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It details a 'Type of capital measure' which is a 'Conditional capital increase' and states the 'New total number of voting rights' as 553,497,393 as of 31.03.2017. This type of announcement, which reports changes in the total number of shares/voting rights, is a specific regulatory disclosure. While it relates to capital structure, it is not a general financing update (CAP) or a share issue/buyback report (SHA/POS). It is a specific regulatory notification regarding voting rights, which fits best under the general 'Regulatory Filings' (RNS) category as it is a mandatory disclosure under German law that doesn't map perfectly to the other specific US-centric codes, or potentially 'SHA' if interpreted broadly as a capital change notification. Given the context of mandatory regulatory disclosure via DGAP (a service for regulatory announcements), RNS is the most appropriate fallback/general regulatory category for this specific type of non-standard filing, although it is a very specific type of capital change notification. Since there is no specific code for 'Total Voting Rights Announcement', RNS is the best fit as a general regulatory filing.
2017-03-31 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.